One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Regeneron (NASDAQ: REGN) Delayed: 798.17 +13.32 (1.70%)
Previous Close $784.85    52 Week High $592.36 
Open $786.03    52 Week Low $325.35 
Day High $801.44    P/E 209.49 
Day Low $779.96    EPS $3.81 
Volume 704,524